Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer Full Text
Investigational New Drugs,
Baker AF et al. – The regimen was not well tolerated and was associated with fatigue and a greater number of gastrointestinal side effects as compared to previously reported experiences in different patient populations. However, the study subjects did experience less bone marrow suppression. The lack of tolerability could reflect the degree of tumor burden within the peritoneal cavity as well as the high number of prior regimens (median of 5) received by the patients participating in this study.